8-K: Precision BioSciences Accelerates PBGENE-DMD Development, Highlights Pre-clinical Data

Precision BioSciences is prioritizing and accelerating the development of PBGENE-DMD, a gene editing approach for Duchenne Muscular Dystrophy, and presented pre-clinical evidence at the ASGCT Annual Meeting.

Summary

• Precision BioSciences is advancing PBGENE-DMD, an in vivo gene editing therapy for Duchenne Muscular Dystrophy (DMD).
• PBGENE-DMD targets mutations in the dystrophin gene, specifically exons 45-55, which affect up to 60% of DMD patients.
• Preclinical data shows PBGENE-DMD leads to significant and sustained improvement in muscle function by restoring functional dystrophin protein production.
• The company plans to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025, with clinical data expected in 2026.
• To focus on PBGENE-DMD and PBGENE-HBV, Precision will pause development of PBGENE-3243 after Phase 1 trial completion.
• The company believes its current cash runway is sufficient to advance both PBGENE-HBV and PBGENE-DMD through Phase 1 clinical readouts.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the acceleration of a promising DMD treatment and positive preclinical data. However, the pause in development of another program and the inherent risks associated with clinical trials temper the overall sentiment.

Positives

• PBGENE-DMD shows potential for durable functional improvement in DMD patients, addressing a significant unmet need.
• Preclinical data indicates significant and sustained improvement in muscle function.
• The company is targeting IND/CTA submission in 2025, indicating rapid progress towards clinical trials.
• PBGENE-DMD has the potential to provide a one-time, durable intervention that could allow for lifelong benefits in muscle regeneration and function.
• The company believes its current cash runway is sufficient to advance both PBGENE-HBV and PBGENE-DMD through Phase 1 clinical readouts.

Negatives

• Development of PBGENE-3243 is being paused to prioritize PBGENE-DMD and PBGENE-HBV, potentially delaying treatment for m.3243-associated mitochondrial disease.

Risks

• The success of PBGENE-DMD is dependent on positive clinical trial outcomes, which are inherently uncertain.
• Pausing development of PBGENE-3243 could impact the company's long-term pipeline and diversification.
• The company's cash runway is only projected to last through Phase 1 clinical readouts for PBGENE-HBV and PBGENE-DMD, potentially requiring additional funding in the future.
• There are risks associated with gene editing technologies, including potential off-target effects and immune responses.

Future Outlook

Precision BioSciences aims to submit an IND and/or CTA for PBGENE-DMD in 2025 and anticipates clinical data in 2026. The company expects its current cash runway to support PBGENE-HBV and PBGENE-DMD through Phase 1 clinical readouts.

Management Comments

• Michael Amoroso, President and Chief Executive Officer of Precision BioSciences, stated that the nomination and acceleration of PBGENE-DMD is a result of compelling preclinical evidence.
• Michael Amoroso stated that PBGENE-DMD has the potential to transform the treatment paradigm and deliver durable functional improvement for most patients.
• Cassie Gorsuch, Ph.D., Chief Scientific Officer at Precision BioSciences, stated that preclinical models have shown that PBGENE-DMD results in significant and sustained improvement of maximum force output.
• Michael Amoroso stated that the company remains excited about the potential for PBGENE-3243 to help people living with m.3243 mitochondrial diseases in the future, alone or through partnerships.

Industry Context

This announcement positions Precision BioSciences in the competitive gene editing landscape, particularly in the area of Duchenne Muscular Dystrophy, where there is a high unmet need for effective treatments. The company's ARCUS platform is being leveraged to develop in vivo gene editing therapies, potentially offering a novel approach compared to existing treatments.

Comparison to Industry Standards

• Companies like Sarepta Therapeutics and Solid Biosciences are also developing gene therapies for DMD, but Precision's ARCUS platform offers a different approach to gene editing.
• Sarepta's Exondys 51, Amondys 45, and Vyondys 53 are exon-skipping therapies, while Solid Biosciences is developing a gene transfer therapy called SGT-001.
• PBGENE-DMD's approach of excising exons 45-55 using ARCUS nucleases distinguishes it from these other therapies.
• The preclinical data showing durable functional improvement in a humanized DMD mouse model is promising and could potentially translate to better clinical outcomes compared to existing treatments.

Stakeholder Impact

• Shareholders may react positively to the accelerated development of PBGENE-DMD and the potential for a new treatment for DMD.
• DMD patients and their families may be encouraged by the potential for a durable functional improvement with PBGENE-DMD.
• Employees may be affected by the prioritization of certain programs and the pausing of others.
• The company's focus on PBGENE-DMD and PBGENE-HBV may impact its relationships with partners and collaborators in other areas.

Next Steps

• Precision BioSciences plans to submit an IND and/or CTA for PBGENE-DMD in 2025.
• The company will advance PBGENE-HBV through Phase 1 clinical trials.
• Precision will continue to monitor and potentially partner for the future development of PBGENE-3243.
• Precision will host a conference call on May 15, 2025, to discuss the update on PBGENE-DMD.

Key Dates

Keywords

PBGENE-DMD, Duchenne Muscular Dystrophy, Gene Editing, Precision BioSciences, ARCUS, Clinical Trial, IND, CTA, PBGENE-HBV, PBGENE-3243